ObsEva announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as CEO of the company effective on or about May 1st, 2023. Prior to joining ObsEva, Mr. de Ladonchamps held a variety of management roles at Addex Therapeutics, from 2008 to 2013. The Company’s Interim Chief Executive Officer, Will Brown, will serve in that position until Mr. Ladonchamps’ effective date of service on May 1, 2023.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OBSV:
- ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
- ObsEva announces delisting from Nasdaq Capital Market
- ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
- ObsEva CEO Brian O’Callaghan steps down
- ObsEva Chairwoman Annette Clancy will not stand for re-election